EYPT News and Press, EyePoint Pharmaceuticals Inc. From 08/01/22

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD PR Newswire -Topline data expected in the second half of 2023- WATERTOWN, Mass. , Aug. 1, 2022 /PRNewswir...

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call an...

EyePoint Pharmaceuticals ( NASDAQ: EYPT ) will highlight historical and ongoing developments for its lead pipeline program, EYP-1901 and its Durasert platform technology, and will also provide a financial update during its Investor Day today. Phase 2 clinical trials for we...

- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 Annual Meeting - Phase 2 clinical trial (DAVIO 2) in wet AMD and in non-proliferative diabetic retinopathy (NPDR) patient dosing a...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

Gainers: Vertical Aerospace ( EVTL ) +31% . NexImmune ( NEXI ) +31% . 180 Life Sciences ( ATNF ) +21% . ToughBuilt Industries ( TBLT ) +20% . Energy Vault Holdings ( NRGV ) +17% . EyePoint Pharmaceuticals ( EYPT ) +...

EyePoint Pharmaceuticals ( NASDAQ: EYPT ) on Friday announced what it deemed to be positive 12-month data from its phase 1 trial for its EYP-1901 therapy as a potential every six-month treatment for wet age-related macular degeneration (wAMD), a chronic eye disorder. E...

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD PR Newswire Data reinforces strong safety and efficacy for EYP-1901 as a potential six-month maintenance tre...

- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas - WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT),...

WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej ...